Treatment and Risk Factors for Recurrence after Curative Resection of Gastrointestinal Stromal Tumors of the Stomach
- 18 September 2004
- journal article
- review article
- Published by Wiley in World Journal of Surgery
- Vol. 28 (9) , 870-875
- https://doi.org/10.1007/s00268-004-7418-0
Abstract
The current definitive treatment for gastrointestinal stromal tumor (GIST) of the stomach is complete resection. GIST has a highly variable clinical course, and recurrent disease sometimes develops despite curative treatment. Although several known risk factors for recurrence exist, adequate treatment strategies are lacking. This study evaluated factors associated with relapse after curative treatment. Sixty patients with gastric GIST were identified from a hospital disease registry database. Clinicopathologic characteristics of these patients were reviewed and the Cox proportional hazards regression analysis was used to identify recurrent risk factors. With a median follow-up of 60 months (range 5–286 months), recurrence occurred in eight (13%) patients, three of whom underwent resection of the recurrent disease and are alive to date. Univariate analysis demonstrated that invasion of the adjacent organs (p = 0.0005), tumor size (p = 0.0046), and expression of proliferative markers [MIB-1 proliferative index (PI) ≥ 10%] (p = 0.0001) were significant risk factors for recurrence. Multivariate analysis with these three factors as variables revealed that only MIB-1 PI was a significant independent risk factor for recurrence (p = 0.0051). In conclusion, surgical resection may be indicated whenever a recurrent GIST is considered resectable. A high MIB-1 PI was identified as an independent indicator of risk for recurrent disease following curative surgery.Keywords
This publication has 34 references indexed in Scilit:
- Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) eraSurgery, 2003
- Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patientsGastric Cancer, 2003
- Ki‐67 expression in breast carcinomaCancer, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- The Effect of Surgery and Grade on Outcome of Gastrointestinal Stromal TumorsArchives of Surgery, 2001
- Prognostic Values of Stromal Proportion and PCNA, Ki-67, and p53 Proteins in Patients with Resected Adenocarcinoma of the LungLaboratory Investigation, 2000
- Stromal Tumors of the Duodenum A Histologic and Immunohistochemical Study of 20 CasesThe American Journal of Surgical Pathology, 1995
- Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas Implications for Surgical Management and StagingAnnals of Surgery, 1992
- Gastric leiomyosarcoma: Clinical and pathological review of fifty patientsJournal of Surgical Oncology, 1981